Soleus Capital Management’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Soleus Capital Management’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-80,000	Closed	-$3.72M	–	125
2023 Q2	$3.72M	Sell	80,000 -93,447	-54%	-$3.23M	0.41%	58
2023 Q1	$4.97M	Hold	173,447	–	–	0.51%	51
2022 Q4	$5.41M	Sell	173,447 -361,911	-68%	-$11.8M	0.78%	37
2022 Q3	$10.9M	Sell	535,358 -280,382	-34%	-$5.11M	1.48%	23
2022 Q2	$12.7M	Sell	815,740 -168,254	-17%	-$2.89M	1.98%	16
2022 Q1	$18.8M	Buy	983,994 +173,054	+21%	+$3.09M	2.43%	14
2021 Q4	$20.5M	Sell	810,940 -68,963	-8%	-$2.02M	2.05%	17
2021 Q3	$28.8M	Buy	+879,903	New	+$30M	4.49%	4

Soleus Capital Management's DICE Position: Q3 2023 in Review

Soleus Capital Management sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 80,000 shares — an estimated $3.72M sold.

Soleus Capital Management first reported a position in DICE in Q3 2021 and held it in 8 quarters. The position peaked at $28.8M in Q3 2021. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

Soleus Capital Management reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Soleus Capital Management sold 80,000 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $3.72M.
Soleus Capital Management first reported a position in DICE Therapeutics, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
Soleus Capital Management's DICE Therapeutics, Inc. Common Stock position peaked at $28.8M in Q3 2021.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Soleus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.